Carfilzomib in addition to lenalidomide and dexamethasone in Asian patients with RRMM outside of a clinical trial

Carfilzomib, lenalidomide, and dexamethasone (KRd) effectively improve survival in patients with relapsed and refractory multiple myeloma (RRMM). However, the outcome of KRd treatment in Asian patients reflecting a general RRMM population outside of a clinical trial has not been reported. Fifty-five...

Full description

Saved in:
Bibliographic Details
Published in:Annals of hematology 2021-08, Vol.100 (8), p.2051-2059
Main Authors: Lee, Ji Hyun, Park, Yong, Kang, Ka-Won, Lee, Je-Jung, Lee, Ho Sup, Eom, Hyeon-Seok, Do, Young Rok, Kim, Jin Seok, Yoon, Sung-Soo, Shin, Dong-Yeop, Koh, Youngil, Kim, Ki-Hyun, Lee, Won Sik, Jo, Jae-Cheol, Lee, Yoo Jin, Lee, Ji Yun, Kim, Dae Sik, Shim, Hyeok, Chang, Myung Hee, Kim, Sung-Hyun, Min, Chang-Ki
Format: Article
Language:English
Subjects:
Clinical trials
Hematology
Immunotherapy
Inhibitor drugs
Medicine
Medicine & Public Health
Oncology
Original Article
Steroids
Targeted cancer therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Carfilzomib, lenalidomide, and dexamethasone (KRd) effectively improve survival in patients with relapsed and refractory multiple myeloma (RRMM). However, the outcome of KRd treatment in Asian patients reflecting a general RRMM population outside of a clinical trial has not been reported. Fifty-five RRMM patients who were treated with carfilzomib in combination with Rd from the time of the first approval of KRd in the Republic of Korea were analyzed. The median age was 61 years. The percentage of patients with an ECOG performance status ≥ 3, creatinine clearance < 50 mL/min, high-risk cytogenetics, and ≥ 4 lines of prior treatment were 9%, 22%, 31%, and 27%, respectively. Forty-one patients started treatment with KRd, whereas the remaining 14 patients (25%) were added carfilzomib during the Rd treatment. In the whole cohort, the overall response rate was 73% and progression-free survival was 8.8 months. The addition of carfilzomib in patients who were refractory or had disease progression during Rd treatment reattained a response in half of the patients. The advantage of carfilzomib with Rd was significant in patients in the first relapse. Toxicity profile was acceptable, excluding severe infections. Carfilzomib in combination with Rd is effective and has a reasonable adverse event rate in Asian patients with RRMM.
ISSN:0939-5555
1432-0584
DOI:10.1007/s00277-021-04407-0